CliniMACS® Plus System Applications
The CliniMACS® Plus System has been proven successful for a wide range of applications, from cell and gene therapy (CGT) processes to graft engineering strategies, such as stem cell and regulatory T cell enrichment or T cell depletion. It also supports the generation of highly pure T cell, NK cell, and dendritic cell populations. Learn more about the available applications and explore details of the different processes.
CD34+ cell enrichment
Stem cell enrichment in graft engineering
Enrich CD34+ hematopoietic stem cells (HSCs) and passively deplete unwanted cells for autologous and allogeneic hematopoietic stem cell transplantation (HSCT). The CliniMACS Plus System generates CD34+ stem cell products of up to 95% purity and with up to a 4.5 log10 depletion of T cells. The enriched product is ideal for HSCT or subsequent HSC engineering.
HSC engineering
As described above, the CD34+ HSC enrichment process is a critical first step in several complex cell manufacturing workflows. Follow the link below to discover how high-quality stem cell enrichment is performed on the CliniMACS Plus to produce gene-engineered HSCs in the following steps.
T cell enrichment and depletion
T cell enrichment for CGT manufacturing workflows
Isolate CD4+ T cells, CD8+ T cells, or combined CD4+/CD8+ T cell fractions with high purity and yield. As enriched T cell populations are frequently used in cell and gene therapy manufacturing, high-quality starting material is critical for downstream workflows.
If you have further interest in this application, please request expert advice.
Targeted TCRα/β+ or CD3+ T cell depletion in graft engineering
Active removal of certain T cell subsets from grafts, with the option of simultaneous B cell depletion, is a means to reduce the risk of graft-versus-host disease (GVHD) and facilitate engraftment. Dedicated depletion systems on the CliniMACS Plus Instrument automate the modification of grafts in closed processing workflows, leaving cells of potential therapeutic benefit in the final product.
TCRγ/δ+ (γδ) T cell manufacturing
Depletion of TCRα/β+ or αβ T cells on the CliniMACS Plus is also part of the workflow for CAR γδ T cell manufacturing. Discover how the modular cell separation step is critical for high-quality cell engineering.
Memory T cell enrichment
Efficient CD45RA+ cell depletion generates memory T cells to fight infection
Donor-derived memory T cells provide immunologic memory against numerous invaders but are less alloreactive than naive T cells, as demonstrated in allogeneic HSCT settings. Memory T cell products for clinical use can be manufactured within 4–7 hours in a closed and sterile system using CliniMACS CD45RA Reagents on the CliniMACS Plus Instrument.
Regulatory T (Treg) cell enrichment
Clinical-grade regulatory T cell manufacturing
Cell separation on the CliniMACS Plus Instrument is an easy and GMP-compliant method to magnetically isolate your CD25high Treg cells, with or without prior depletion of CD8+ and/or CD19+ cells with high purity and recovery. Follow the link and learn more about Treg enrichment and expansion strategies.
Natural killer (NK) cell enrichment
Purified NK cells for immunotherapy: solutions for clinical-grade NK cell separation
Efficient and pure cell separation is essential to prepare donor-derived NK cells for adoptive cell therapy, from minimally manipulated products to advanced NK cell-based therapies. Our two-step clinical-grade NK cell separation depletes CD3+ cells and enriches CD56+ cells using the closed and sterile CliniMACS Plus System.
Dendritic cell (DC) enrichment
Clinical-grade isolation of blood DC subsets
Magnetic cell separation on the CliniMACS Plus is a simple method for efficiently isolating rare subsets of cells, such as blood DCs, in an automated and closed fashion. Depletion of CD19+ cells and labeling of CD1c (BDCA-1)+ cells or enrichment of CD304 (BDCA-4)+ dendritic cells can be performed on CliniMACS Plus.
Enrichment of CD14+ cells for Mo-DC generation
Monocyte-derived dendritic cells (Mo-DCs) are the most widely used subset of DCs for clinical trials. In the first step of Mo-DC generation, the CliniMACS Plus System is used for in vitro enrichment of CD14+ cells with high purity and yield from heterogeneous hematological cell populations. DCs are then differentiated ex vivo from peripheral blood CD14+ monocytes in the presence of recombinant GM-CSF and IL-4.